In vitro/in vivo correlation and modeling of emitted dose and lung deposition of inhaled XXXX from metered dose inhalers with different types of spacers in noninvasively ventilated @entity1 .

@entity1 @entity3045 @entity4185 @entity1274 @entity400
UNASSIGNED: Substituting spacer by another in noninvasive ventilation (NIV) involves many variables, e.g. total emitted dose (TED), mass median aerodynamic diameter (MMAD), type of spacer, total lung deposition and total systemic absorption, which must be adjusted to ensure @entity1 optimum therapy. Data mining based on artificial @entity1274 and genetic algorithms were used to model in vitro inhalation process, predict and optimize bioavailability from inhaled doses delivered by @entity4185 ( @entity4185 ) using different spacers in NIV. Modeling of data indicated that in vitro performance of @entity4185 -spacer systems was dependent mainly on fine particle dose (FPD), @entity400 ( @entity400 ), MMAD and to lesser extent on spacer type. Ex vivo model indicated that amount of @entity3045 collected on facemask filter was directly affected by @entity400 . In vivo model (24hQ) depended directly on spacer type, @entity400 and TED. Female @entity1 showed higher 0.5hQ and 24hQ values than males. AeroChamber VC spacer demonstrated higher TED and 24hQ in vivo values. Results indicated suitability of @entity4185 -spacer systems in achieving appropriate in vitro inhalation performance. The possibility of modeling and predicting both ex vivo and in vivo capabilities of @entity4185 -spacer systems from knowledge of in vitro attributes enabled detailed focus on important variables required to deliver safe and accurate doses of @entity3045 to ventilated @entity1 .
